Pcn48 Non-Adherence to Imatinib in Chronic Myeloid Leukemia (Cml) Patients Is Associated With Short- And Long-Term Negative Impacts on Health Care Resource Utilization and Costs

Guérin, Annie; Bollu, Vamsi; Guo, Amy; Wu, EQ; Yu, AP; Sirulnik, LA; Griffin, JD

doi:10.1016/s1098-3015(10)72137-9

Cited by 4 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of patients included in each study ranged from 19 [11] to 2,145 [57] with a mean number of 292 patients. There was wide variation in the methods used to assess medication adherence, ranging from patient self-report (n=17; 33%) [5,6,9,10,31,34,37,44,45,51,60,61,[64][65][66][67][68], claims data (n = 12; 23%) [13,14,32,36,38,39,41,49,50,[54][55][56], Medication Event Monitoring Systems (MEMS) (n=7; 13%) [4,8,29,42,43,47,59]; chart review (n=6; 12%) [11,40,44,61,65,68] and pill counts (n = 4; 7.7%) [5,30,48,…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…Thirty three percent (n=15) [4,8,13,14,32,37,39,41,46,50,54,56,64,66,67] of the publications describing quantitative outcomes and six of the seven [35,55,60,[62][63][64] publications employing qualitative methods were classified as demonstrating acceptable levels of methodological quality. Of the publications reporting on quantitative outcomes, the most poorly addressed methodological quality indicators were 'being free from conflict of interest' (n=35) [5, 8, 11, 13, 14, 27, 29-34, 36, 38-52, 54-57, 65, 66, 68] and 'appropriate control for bias' (n=27) [4, 6, 9-11, 27-31, 33, 36, 38, 40, 42-45, 47, 51, 52, 59-61, 65, 68, 69].…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…As shown in Table 2, the measures and definitions of medication adherence varied between studies. Some studies reported adherence as a percentage rate [5, 6, 8, 29, 30, 32, 36, 40, 42-44, 47, 48], others reported a mean adherence rate [5, 8-10, 28-30, 32, 36, 42, 43, 47], some reported the score from an adherence measure [5,13,38,39,46,50,52,54,55], while others classified patients into categories of adherence, such as low, medium and high levels of adherence [11,13,14,28,31,32,34,37,40,41,45,46,50,52,55]. Such variation prohibits the ability to combine data and adequately estimate the rate of medication adherence in CML patients.…”

Section: CMLmentioning

confidence: 99%

“…[5][6][7][8][9][10][11][12] Non-adherence has been found to be associated with increased health care utilisation including increased physician visits, higher rates of hospitalisation and longer average length of time spent in hospital, [3,7,13] as well as higher medical service costs. [13,14] Medication adherence is related to disease type [15] and disease related factors. [7] The degree of adherence and the factors affecting adherence need to be assessed and addressed at a disease specific level.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients

Hall

Paul

Bryant

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

To conduct a comprehensive review to examine among hematological cancer patients: (1) rates of adherence to self-administered cancer treatments; and (2) factors impacting on their adherence. Fifty two eligible publications were identified. The majority focused on Chronic Myeloid Leukaemia (CML) (n=40) and Acute Lymphoid Leukaemia (ALL) (n=11) patients. Adherence rates varied and depended on the definition and measures used. Patient understanding about their disease and treatment, and forgetting to take their medication impacted on patients' level of adherence; while the use of reminders reduced forgetfulness. There is a lack of valid and reliable information relating to medication adherence of hematological cancer patients. Based on the limited data available we provide a profile of CML and ALL patients at potential risk of medication non-adherence, as well as a proposed checklist that can be used by health care providers in assessing and supporting patients in adhering to their medication.

show abstract

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: CMLmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients

Hall

Paul

Bryant

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

show abstract

“…[10][11][12][13][14] Nonuse of prescribed cancer medicines is also associated with increased physician visits, higher rates of hospitalisation, longer average length of time spent in hospital for cancer patients 12,15,16 and higher health service costs. 15,17 In Australia, little is known about the proportion of cancer patients who do not take prescribed or recommended medications as a result of cost-related factors. The importance of this issue is reflected in the position statements of cancer advocacy groups.…”

mentioning

confidence: 99%

The impact of loss of income and medicine costs on the financial burden for cancer patients in Australia

Paul¹,

Boyes²,

Searles³

et al. 2016

J Community Support Oncol

View full text Add to dashboard Cite

Background The cost of medicines may prove prohibitive for some cancer patients, potentially reducing the ability of a health system to fully deliver best practice care. Objective To identify nonuse or nonpurchase of cancer-related medicines due to cost, and to describe the perceived financial burden of such medicines and associated patient characteristics. Methods A cross-sectional pen-and-paper questionnaire was completed by oncology outpatients at 2 hospitals in Australia; 1 in regional New South Wales and 1 in metropolitan Victoria. Results Almost 1 in 10 study participants had used over-the-counter medicines rather than prescribed medicines for cancer and obtained some but not all of the medicines prescribed in relation to their cancer. 63% of the sample reported some level of financial burden associated with obtaining these medicines, with 34% reporting a moderate or heavy financial burden. 11.8% reported using alternatives to prescribed medicines. People reporting reduced income after being diagnosed with cancer had almost 4 times the odds (OR, 3.73; 95% CI, 1.1-12.1) of reporting a heavy or extreme financial burden associated with prescribed medicines for cancer. Limitations Study response rate, narrow survey population, self-reported survey used. Conclusion This study identifies that a number of cancer patients, especially those with a reduced income after their diagnosis, experience financial burden associated with the purchase of medicines and that some go as far as to not use or to not purchase medicines. It seems likely that limiting the cost of medicines for cancer may improve patient ability to fully participate in the intended treatment.

show abstract

Primary Localized Gastrointestinal Stromal Tumors: Medication Adherence and Prognosis According to Gender

Ran

et al. 2022

PPA

View full text Add to dashboard Cite

Objective Gender is associated with medication adherence for imatinib, but whether it is related to the prognosis of primary localized gastrointestinal stromal tumors (GISTs) is unclear. The goal of this study was to clarify the relationship between gender and prognosis in GIST patients, with differences in medication adherence considered. Methods The data of 320 GIST patients were retrospectively collected from the First Affiliated Hospital of Chongqing Medical University. Survival analysis was performed using the Kaplan–Meier method (Log rank test) and the risk factors of recurrence were determined using Cox multivariate analysis. Medication adherence-stratified analyses were performed to control for confounding factors. Results Kaplan–Meier analysis revealed that among patients who received postoperative adjuvant imatinib therapy, men had a higher recurrence rate than women ( P <0.01). Pearson’s chi-square test revealed better medication adherence in women than in men ( P <0.01). Cox regression analysis revealed that gender was not an independent risk factor for recurrence-free survival (RFS; P =0.25), but medication adherence was ( P <0.01). Among GIST patients with a medication possession ratio (MPR) of less than 90%, 62.86% of male patients took imatinib irregularly or not at all due to limited understanding of the disease, whereas 55.74% of female patients’ took imatinib irregularly because they could not tolerate adverse drug reactions. Conclusion Adherence was poorer in male than in female patients, which might explain the worse prognoses of the former among patients who received adjuvant treatment with imatinib. The gender difference in the degree of adherence should be considered in postoperative pharmacotherapy for patients with primary localized GISTs.

show abstract

Pcn48 Non-Adherence to Imatinib in Chronic Myeloid Leukemia (Cml) Patients Is Associated With Short- And Long-Term Negative Impacts on Health Care Resource Utilization and Costs

Cited by 4 publications

References 0 publications

To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients

To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients

The impact of loss of income and medicine costs on the financial burden for cancer patients in Australia

Primary Localized Gastrointestinal Stromal Tumors: Medication Adherence and Prognosis According to Gender

Contact Info

Product

Resources

About